Diversigen, Baylor Miraca Form Partnership

February 26th, 2016
Posted by


 

clinical_studies

The recent partnership between Diversigen and Baylor Miraca Genetics highlights the importance of both human genetics and the microbiome in drug development and ultimately in clinical decision making.

We are in the early days of understanding the scope of the impact of the microbiome but we already know of powerful associations in diseases as diverse as inflammatory bowel disease, diabetes and cancer.

We are excited about this partnership as it leverages real technical and interpretive expertise across across a broad array of genomes relevant to human health.

Read more about their partnership.


Like this content? Don’t miss an update.


About the Author:

I founded Popper and Company with Ken Walz more than ten years ago to address inefficiencies in health care by helping life science companies develop and commercialize new technology. Today, the members of our growing team leverage their extensive knowledge of the tools and trends shaping all aspects of health care and its participants. Send me an email.